Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Purpose: The genomic landscape of gliomas has been characterized and now contributes to disease classification, yet the relationship between molecular profile and disease progression and treatment response remain poorly understood. Experimental Design: We integrated prospective clinical sequencing of 1,004 primary and recurrent tumors from 923 glioma patients with clinical and treatment phenotypes. Results: Thirteen percent of glioma patients harbored a pathogenic germline variant, including a subset associated with heritable genetic syndromes and variants mediating DNA repair dysfunctions (29% of the total) that were associated with somatic biallelic inactivation and mechanism-specific somatic phenotypes. In astrocytomas, genomic alterations in effectors of cell-cycle progression correlated with aggressive disease independent of IDH mutation status, arose preferentially in enhancing tumors (44% vs. 8%, P < 0.001), were associated with rapid disease progression following tumor recurrence (HR = 2.6, P = 0.02), and likely preceded the acquisition of alkylating therapy-associated somatic hypermutation. Thirty-two percent of patients harbored a potentially therapeutically actionable lesion, of whom 11% received targeted therapies. In BRAF-mutant gliomas, response to agents targeting the RAF/MEK/ERK signaling axis was influenced by the type of mutation, its clonality, and its cellular and genomic context. Conclusions: These data reveal genomic correlates of disease progression and treatment response in diverse types of glioma and highlight the potential utility of incorporating genomic information into the clinical decision-making for patients with glioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 1×
“Many of these therapies targeted mutant effectors of aberrant RTK/MAPK signaling including RAF and MEK inhibitors now used routinely to treat patients with diverse cancer types with activating BRAF mutations (28-30).”
BackgroundVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 3×
“Molecular characterization of previously untreated gliomas has established the landscape of genomic alterations (1-5).”
BackgroundResultSelf-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Self-citationZehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“Both platforms cover protein-coding exons of cancerassociated genes, as previously described (12-14), and detect somatic single-nucleotide variants, insertions, deletions, copy-number alterations, and certain gene fusions and structural variants.”
BackgroundSelf-citationComprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148 · cited 4×
“22), The Cancer Genome Atlas (1, 2) and Foundation Medicine (894 and 739 samples, respectively, both https://portal.”
BackgroundInfluentialFrampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 1×
“Both platforms cover protein-coding exons of cancerassociated genes, as previously described (12-14), and detect somatic single-nucleotide variants, insertions, deletions, copy-number alterations, and certain gene fusions and structural variants.”
BackgroundMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationAACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964 · cited 4×
“To increase our statistical power to identify novel mutational hotspots in known glioma genes such as EGFR and PDGFRA, we combined our prospective cohort with retrospectively sequenced glioma cohorts (n=3,130 sequenced gliomas) (2,3,22).”
BackgroundMethodInfluentialSelf-citationVemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · cited 1×
“Many of these therapies targeted mutant effectors of aberrant RTK/MAPK signaling including RAF and MEK inhibitors now used routinely to treat patients with diverse cancer types with activating BRAF mutations (28-30).”
BackgroundSelf-citation
Cited by
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review
Schaff, L. R., & Mellinghoff, I. K. (2023) · JAMA · doi:10.1001/jama.2023.0023 · Cited by 1,271
Self-citationWen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationMechanisms and therapeutic implications of hypermutation in gliomas
Touat, M., Li, Y. Y., Boynton, A. N., Spurr, L. F., Iorgulescu, J. B., Bohrson, C. L., Cortes-Ciriano, I., Birzu, C., Geduldig, J. E., Pelton, K., et al. (2020) · Nature · doi:10.1038/s41586-020-2209-9 · Cited by 677
Harnessing multimodal data integration to advance precision oncology
Boehm, K. M., Khosravi, P., Vanguri, R., Gao, J., & Shah, S. P. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00408-3 · Cited by 662
“This leads to further understanding of the cancer genome, drug sensitivity 2 and resistance mechanisms 3 , and prognostic associations 4,5 .”
BackgroundIvosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
Mellinghoff, I. K., Ellingson, B. M., Touat, M., Maher, E., De La Fuente, M. I., Holdhoff, M., Cote, G. M., Burris, H., Janku, F., Young, R. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03327 · Cited by 324
Self-citation
Metadata
- Authors
- Jonsson, P., Lin, A. L., Young, R. J., DiStefano, N. M., Hyman, D. M., Li, B. T., Berger, M. F., Zehir, A., Ladanyi, M., Solit, D. B., Arnold, A. G., Stadler, Z. K., Mandelker, D., Goldberg, M. E., Chmielecki, J., Pourmaleki, M., Ogilvie, S. Q., Chavan, S. S., McKeown, A. T., Manne, M., Hyde, A., Beal, K., Yang, T. J., Nolan, C. P., Pentsova, E., Omuro, A., Gavrilovic, I. T., Kaley, T. J., Diamond, E. L., Stone, J. B., Grommes, C., Boire, A., Daras, M., Piotrowski, A. F., Miller, A. M., Gutin, P. H., Chan, T. A., Tabar, V. S., Brennan, C. W., Rosenblum, M., DeAngelis, L. M., Mellinghoff, I. K., & Taylor, B. S.
- Venue
- Clinical Cancer Research
- Published
- 2019-09-13
- Volume
- 25
- Issue
- 18
- Pages
- 5537-5547
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2954309731
- Cited by
- 157
- References
- 15
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-0032
- The paper
- Jonsson, P., Lin, A. L., Young, R. J., DiStefano, N. M., Hyman, D. M., Li, B. T., Berger, M. F., Zehir, A., Ladanyi, M., Solit, D. B., Arnold, A. G., Stadler, Z. K., Mandelker, D., Goldberg, M. E., Chmielecki, J., Pourmaleki, M., Ogilvie, S. Q., Chavan, S. S., McKeown, A. T., . . . Taylor, B. S. (2019). Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.